You are here

Generic Zemplar (Paricalcitol) Launched in U.S.

Active form of vitamin D treats hyperparathyroidism (October 1)

A generic equivalent of Zemplar (paricalcitol) tablets is now available in the U.S. The generic drug was launched on Sept. 30 by Teva Pharmaceutical Industries.

Paricalcitol is an active form of vitamin D used to prevent and treat secondary hyperparathyroidism (increased parathyroid hormone levels) in patients with stage-3 or -4 chronic kidney disease and in stage-5 patients on dialysis.

Marketed by AbbVie Inc., brand-name Zemplar had annual sales of approximately $115 million in the U.S., according to IMS data as of June 30, 2013.

Source: Teva; October 1, 2013.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs